[HTML][HTML] Effects of sevelamer treatment on cardiovascular abnormalities in mice with chronic renal failure
J Maizel, I Six, S Dupont, E Secq, B Dehedin… - Kidney international, 2013 - Elsevier
Elevated serum phosphate and fibroblast growth factor 23 (FGF23) levels are associated
with cardiovascular disease (CVD) in patients with chronic renal failure (CRF). The …
with cardiovascular disease (CVD) in patients with chronic renal failure (CRF). The …
Cardiovascular effects of sevelamer in stage 3 CKD
CD Chue, JN Townend, WE Moody… - Journal of the …, 2013 - journals.lww.com
Serum phosphate independently predicts cardiovascular mortality in the general population
and CKD, even when levels are in the normal range. Associations between serum …
and CKD, even when levels are in the normal range. Associations between serum …
Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial
BACKGROUND: Fibroblast growth factor 23 (FGF-23) is a marker of endothelial dysfunction
and atherosclerotic complications in patients with chronic kidney disease (CKD). Because …
and atherosclerotic complications in patients with chronic kidney disease (CKD). Because …
Sevelamer revisited: pleiotropic effects on endothelial and cardiovascular risk factors in chronic kidney disease and end-stage renal disease
A Rastogi - Therapeutic advances in cardiovascular disease, 2013 - journals.sagepub.com
Endothelial dysfunction underlies multiple cardiovascular consequences of chronic kidney
disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end …
disease (CKD) and antecedent diabetes or hypertension. Endothelial insults in CKD or end …
Short-term effects of sevelamer-carbonate on fibroblast growth factor 23 and pulse wave velocity in patients with normophosphataemic chronic kidney disease Stage 3
A Bouma-de Krijger, FJ van Ittersum… - Clinical kidney …, 2019 - academic.oup.com
Background High concentrations of both phosphate and fibroblast growth factor 23 (FGF23)
observed in chronic kidney disease (CKD) are associated with an increased risk of …
observed in chronic kidney disease (CKD) are associated with an increased risk of …
Effects of sucroferric oxyhydroxide compared to lanthanum carbonate and sevelamer carbonate on phosphate homeostasis and vascular calcifications in a rat model …
O Phan, M Maillard, HH Malluche… - BioMed research …, 2015 - Wiley Online Library
Elevated serum phosphorus, calcium, and fibroblast growth factor 23 (FGF23) levels are
associated with cardiovascular disease in chronic renal disease. This study evaluated the …
associated with cardiovascular disease in chronic renal disease. This study evaluated the …
Emerging effects of sevelamer in chronic kidney disease
R Ikee, M Tsunoda, N Sasaki, N Sato… - Kidney and Blood …, 2013 - karger.com
Sevelamer, a non-absorbable anion exchange resin, is used to control hyperphosphatemia
in chronic kidney disease (CKD) by binding to dietary phosphate in the gastrointestinal tract …
in chronic kidney disease (CKD) by binding to dietary phosphate in the gastrointestinal tract …
[HTML][HTML] Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term experimental uremia
M Cozzolino, ME Staniforth, H Liapis, J Finch… - Kidney international, 2003 - Elsevier
Sevelamer hydrochloride attenuates kidney and cardiovascular calcifications in long-term
experimental uremia. Background In chronic renal failure (CRF), hyperphosphatemia and an …
experimental uremia. Background In chronic renal failure (CRF), hyperphosphatemia and an …
Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency
N Nagano, S Miyata, S Obana… - Nephrology Dialysis …, 2003 - academic.oup.com
Background. Dietary phosphate restriction prevents renal function deterioration in animal
models. This study examined whether sevelamer hydrochloride (Renagel®;'sevelamer' …
models. This study examined whether sevelamer hydrochloride (Renagel®;'sevelamer' …
Long‐term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum K lotho levels in chronic haemodialysis patients
HH Lin, HH Liou, MS Wu, CY Lin, CC Huang - Nephrology, 2014 - Wiley Online Library
Aims Fibroblast growth factor 23 (FGF 23) and K lotho are associated with vascular
calcification and cardiovascular disease in dialysis patients. Sevelamer has been shown to …
calcification and cardiovascular disease in dialysis patients. Sevelamer has been shown to …